Merck: FDA grants priority review for Keytruda
(CercleFinance.com) - The Food and Drug Administration has agreed to a priority review of Merck's Keytruda for the treatment of Merkel cell carcinoma, a rare form of skin cancer, the company said on Tuesday.
The US FDA has accepted and granted priority review for a new supplemental biologics license application (sBLA) seeking accelerated approval for Merck's anti-PD-1 therapy for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The US FDA has accepted and granted priority review for a new supplemental biologics license application (sBLA) seeking accelerated approval for Merck's anti-PD-1 therapy for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Copyright (c) 2018 CercleFinance.com. All rights reserved.